吸入糖皮质激素后血嗜酸性粒细胞变化或可预测COPD长期临床应答
该研究为ISOLDE试验的事后分析,纳入751例中重度COPD患者,比较每日两次500微克丙酸氟替卡松与安慰剂治疗3年。结果显示,吸入糖皮质激素后1年内血嗜酸性粒细胞计数变化可预测长期治疗应答:EOS抑制≥200 cells·μL-1者FEV1下降减缓32 mL·year-1、急性加重率降低30%;而EOS增加≥200 cells·μL-1者FEV1下降加速37 mL·year-1、急性加重率增加80%(p<0.0001)。
要点
- ICS后1年内EOS变化可预测中重度COPD患者的长期ICS应答。
- EOS抑制≥200 cells·μL-1者ICS治疗FEV1下降减缓32 mL·year-1,急性加重率降低30%。
- EOS增加≥200 cells·μL-1者ICS治疗FEV1下降加速37 mL·year-1,急性加重率增加80%。
核心结论
- ICS给药后血EOS变化可能预测中重度COPD患者的ICS临床应答。
- 在ICS后EOS增加的患者中,ICS使用可能与更频繁的急性加重和加速的肺功能下降相关。
研究设计与样本
- ISOLDE试验的事后分析,该试验为3年双盲随机对照试验,比较每日两次500 µg丙酸氟替卡松与安慰剂。
- 共纳入751例中重度COPD患者。
主要发现
- ICS后1年内EOS变化对治疗应答有强预测作用,EOS受抑制与治疗效应相关。
- EOS抑制≥200 cells·μL-1者,ICS使用与FEV1下降速率减缓32 mL·year-1相关,急性加重率降低30%。
- EOS增加≥200 cells·μL-1者,ICS使用与FEV1下降速率加速37 mL·year-1相关,急性加重率增加80%(p<0.0001)。
- EOS变化不能预测圣乔治呼吸问卷评估的健康状态方面的临床应答。
关键数值与推荐
- EOS抑制≥200 cells·μL-1:FEV1下降减缓32 mL·year-1,急性加重率降低30%。
- EOS增加≥200 cells·μL-1:FEV1下降加速37 mL·year-1,急性加重率增加80%(p<0.0001)。
临床怎么用
- 对中重度COPD患者,ICS治疗后监测血EOS变化可能有助于预测长期ICS应答。
- ICS后EOS增加≥200 cells·μL-1的患者使用ICS可能与急性加重增多和肺功能加速下降相关。
局限性
- 该研究为事后分析,结果属于假说生成性观察,需前瞻性设计研究验证。
- ISOLDE试验开展于ICJME推荐RCT方案前瞻性注册之前。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
There is an emerging role for blood eosinophil count (EOS) as a biomarker to guide inhaled corticosteroid (ICS) therapy in COPD. Since ICS administration could influence EOS, we hypothesised that change in EOS following treatment with ICS may predict outcomes of long-term therapy.In a post hoc analysis of ISOLDE, a 3-year, double-blind trial comparing 500 µg fluticasone propionate twice daily with placebo in 751 patients with moderate-to-severe COPD, we evaluated whether the initial changes in EOS during ICS treatment were predictive of ICS treatment response.EOS change within 1 year after the introduction of ICS was strongly predictive of treatment response. A suppressed EOS was associated with treatment effect. Characteristically, in patients with EOS suppression of ≥200 cells·μL-1, ICS use was associated with a decelerated rate of decline of forced expiratory volume in 1 s (FEV1), by 32 mL·year-1, and a 30% reduction in the exacerbation rate. In contrast, in patients experiencing an increase in EOS of ≥200 cells·μL-1, ICS use was associated with an accelerated rate of decline of FEV1, by 37 mL·year-1 and an 80% increase in the exacerbation rate (p<0.0001). EOS change was not predictive of clinical response with regards to health status evaluated using the St George's Respiratory Questionnaire.These findings suggest that EOS change after ICS administration may predict clinical response to ICS therapy in patients with moderate-to-severe COPD at risk of exacerbations. ICS administration may be associated with more frequent exacerbations and an accelerated lung function decline in the 20% of patients in whom EOS increases after the administration of ICS. These hypothesis-generating observations will need validation in prospectively designed studies.The ISOLDE trial was conducted before the ICJME recommended a prospective registration of RCT protocols.
引用
- Mathioudakis AG, Bikov A, Foden P, et al. Change in blood eosinophils following treatment with inhaled corticosteroids may predict long-term clinical response in COPD. Eur Respir J. 2020. PMID: 32108044. doi:10.1183/13993003.02119-2019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。